These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 22339395)
1. Rituximab: current status as therapy for malignant and benign hematologic disorders. Abdulla NE; Ninan MJ; Markowitz AB BioDrugs; 2012 Apr; 26(2):71-82. PubMed ID: 22339395 [TBL] [Abstract][Full Text] [Related]
2. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma. Bosly A; Keating MJ; Stasi R; Bradstock K Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588 [TBL] [Abstract][Full Text] [Related]
4. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. Dierickx D; Delannoy A; Saja K; Verhoef G; Provan D Am J Hematol; 2011 Mar; 86(3):278-91. PubMed ID: 21328427 [TBL] [Abstract][Full Text] [Related]
5. Treatment with rituximab in benign and malignant hematologic disorders in children. Giulino LB; Bussel JB; Neufeld EJ; J Pediatr; 2007 Apr; 150(4):338-44, 344.e1. PubMed ID: 17382107 [No Abstract] [Full Text] [Related]
7. A review of rituximab in cutaneous medicine. Scheinfeld N Dermatol Online J; 2006 Jan; 12(1):3. PubMed ID: 16638371 [TBL] [Abstract][Full Text] [Related]
8. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Stasi R Semin Hematol; 2010 Apr; 47(2):170-9. PubMed ID: 20350664 [TBL] [Abstract][Full Text] [Related]
9. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Robak T; Lech-Maranda E; Robak P Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624 [TBL] [Abstract][Full Text] [Related]
10. B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic. Shen S; Chan A; Sfikakis PP; Hsiu Ling AL; Detorakis ET; Boboridis KG; Mavrikakis I Surv Ophthalmol; 2013; 58(3):252-65. PubMed ID: 23253433 [TBL] [Abstract][Full Text] [Related]
11. Rituximab. Borker A; Choudhary N Indian Pediatr; 2011 Aug; 48(8):627-32. PubMed ID: 21918268 [TBL] [Abstract][Full Text] [Related]
12. Rituximab immunotherapy for non-Hodgkin's lymphoma. White CA Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310 [TBL] [Abstract][Full Text] [Related]
13. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma]. Tobinai K Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743 [TBL] [Abstract][Full Text] [Related]
14. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases. Tanaka Y Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614 [No Abstract] [Full Text] [Related]
15. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Rastetter W; Molina A; White CA Annu Rev Med; 2004; 55():477-503. PubMed ID: 14746532 [TBL] [Abstract][Full Text] [Related]
16. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020 [TBL] [Abstract][Full Text] [Related]
17. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis]. Roccatello D; Vangelista A; Pani A G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261 [TBL] [Abstract][Full Text] [Related]
18. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Collins-Burow B; Santos ES Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647 [TBL] [Abstract][Full Text] [Related]
19. [Anti-CD20 in hematologic oncology]. Milpied N Presse Med; 2009 May; 38(5):788-98. PubMed ID: 19297126 [TBL] [Abstract][Full Text] [Related]
20. Rituximab and its use in autoimmune bullous disorders. Daniel BS; Murrell DF; Joly P Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]